MGMT negativity resulting from methylation of MGMT may contribute to alkylating agent sensitivity in breast cancer, thereby leading to a longer DFS for patients receiving postoperative adjuvant chemotherapy 19. This evidence concerns the gene MGMT and breast carcinoma.